Projecten per jaar
Persoonlijk profiel
Expertise
Bart Neyns obtained his MD (1992) and PhD (2001) from the Vrije Universiteit Brussel (VUB), Brussels. Dr Neyns held a Research Fellowship supported by the National Fund for Scientific Research (NFWO), at the Laboratory of Medical Oncology, VUB (1992–1996). In 1996, he began furthering his training in Internal Medicine and Medical Oncology, at the same institute, obtaining his Specialist Degree in 1999. Dr Neyns subsequently became a Resident at the Department of Internal Medicine/Medical Oncology, VUB (1999–2002). In 2009, Dr Neyns specialized in Medical Oncology. During 2002–2012 and 2012-2019, he was appointed respectively as Head of Clinic and Head of Division at the Department of Medical Oncology, UZ Brussel, before being appointed to his current position as Head of Department at the same department, in May 2019. He currently holds an additional parallel position as Clinical Professor at the Faculty of Medicine and Pharmacy, VUB (since 2007); between 2010 and 2018 he served as a Dermato-Oncology Consultant at the Erasme Hospital Université Libre de Bruxelles (ULB), Brussels. Dr Neyns is the member of seven national and international scientific societies including, the Belgian Medical Society of Medical Oncology ESMO, and ASCO. He has been the recipient of several competitive research grants, and has considerable clinical trial experience as a Principal Investigator for more than fifteen academia sponsored clinical trials for patients with advanced melanoma, glioma and colorectal cancer; including clinical trials with a proprietary autologous dendritic cell therapy (TriMixDC) and first-in-human phase I clinical trials with intratumoral injection of autologous myeloid dendritic cells. Dr Neyns has an extensive publication record as the (co-)author of over hundred forty primary manuscripts published in peer review medical journals (incl. N Engl J Med, Lancet Oncol, and the J Clin Oncol), and has been invited speaker at several international congresses. His current research interests broadly include the immune- and targeted therapy of melanoma and the treatment of patients with malignant glioma with a strong emphasis on conducting academia sponsored trials.
Vingerafdruk
- 1 Soortgelijke profielen
Netwerk
-
OZR3913: Cofinanciering OZR FWO Hercules MZW - Single-cell eiwit analyse in intacte weefsels
Movahedi, K., van Grunsven, L., Rooman, I., Van Ginderachter, J., Smolders, I., Neyns, B., Vanhaecke, T., Laoui, D., Breckpot, K., De Veirman, K., Stijlemans, B., Van Schependom, J., Magez, S., Goyvaerts, C., De Kock, J., De Leu, N., Massie, A., Hellemans, K., Spits, C., De Bundel, D., De Trez, C., Hernot, S., Van Dooren, S., Aerts, J., Staels, W. & Tuyaerts, S.
25/02/22 → 25/02/26
Project: Fundamenteel
-
-
OZR3588: Financiering FWO Hercules: ERA platform: Uitgebreid RNA Analyse platform - versie 2.0
Rooman, I., Bouwens, L., Heimberg, H., Neyns, B., Vranken, W., Vanhaecke, T., Massie, A., van Grunsven, L., De Bruyne, E., De Bundel, D., Forsyth, R., Breckpot, K., Van Dooren, S., De Kock, J., Njemini, R. & Laoui, D.
1/05/20 → 30/04/24
Project: Fundamenteel
Onderzoeksoutput
-
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors
Awada, G., Schwarze, J. K., Tijtgat, J., Fasolino, G., Kruse, V. & Neyns, B., 1 jun 2022, In : Melanoma Research. 32, 3, blz. 183-191 9 blz.Onderzoeksoutput: Article
-
Antitumor activity of ipilimumab or BRAF +/- MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
Long, G. V., Arance, A., Mortier, L., Lorigan, P., Blank, C., Mohr, P., Schachter, J., Grob, J. -J., Lotem, M., Middleton, M. R., Neyns, B., Steven, N., Ribas, A., Walpole, E., Carlino, M. S., Lebbe, C., Sznol, M., Jensen, E., Leiby, M. A., Ibrahim, N. & 1 anderen, , feb 2022, In : Annals of Oncology. 33, 2, blz. 204-215 12 blz.Onderzoeksoutput: Article
Open Access1 Citaat (Scopus) -
Computer-aided detection and segmentation of malignant melanoma lesions on whole-body 18F-FDG PET/CT using an interpretable deep learning approach
Dirks, I., Keyaerts, M., Neyns, B. & Vandemeulebroucke, J., jun 2022, In : Computer Methods and Programs in Biomedicine. 221, blz. 106902 106902.Onderzoeksoutput: Article
-
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Lenz, H-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., Dragovich, T., Shah, U., Abdullaev, S., Gricar, J., Ledeine, J-M., Overman, M. J. & Lonardi, S., 10 jan 2022, In : Journal of Clinical Oncology. 40, 2, blz. 161-170 10 blz.Onderzoeksoutput: Article
-
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial
Schwarze, J. K., Garaud, S., Jansen, Y., Awada, G., Vandersleyen, V., Tijtgat, J., de Wind, A., Kristanto, P., Seremet, T., Willard-Gallo, K. & Neyns, B., feb 2022, In : Cancers (Basel). 14, 3, 22 blz., 682.Onderzoeksoutput: Article
Open Access
Prijzen
-
Best Poster Award
Gil Awada (Recipient), Ibrahim Özdemir (Recipient), Julia Katharina Schwarze (Recipient), Emma Daeninck (Recipient), Odrade Gondry (Recipient), Yanina Jansen (Recipient), Teofila Seremet (Recipient), Marleen Keyaerts (Recipient), Hendrik Everaert (Recipient) & Bart Neyns (Recipient), 15 dec 2018
Prijs: Prize (including medals and awards)
Activiteiten
-
Human relevant models for drug research and development
Fien Meeus (Speaker), Robin Maximilian Awad (Contributor), Nick Devoogdt (Contributor), Sandra Tuyaerts (Contributor), Cleo Goyvaerts (Contributor), Yannick De Vlaeminck (Contributor), Bart Neyns (Contributor), Karine Breckpot (Contributor)8 okt 2021Activiteit: Talk or presentation at a workshop/seminar
-
A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma
Julia Katharina Schwarze (Presenter), Jens Tijtgat (Contributor), Gil Awada (Contributor), Louise Cras (Contributor), Inès Dufait (Contributor), Ramses Forsyth (Contributor), Sandra Tuyaerts (Contributor), Bart Neyns (Contributor)17 sep 2021Activiteit: Talk or presentation at a conference
-
Melanomen
Guy Verfaillie (Speaker), Valerie Vandersleyen (Speaker), Bart Neyns (Speaker)19 feb 2019Activiteit: Talk or presentation at a workshop/seminar
-
Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab
Gil Awada (Speaker), Ibrahim Özdemir (Contributor), Julia Katharina Schwarze (Contributor), Emma Daeninck (Contributor), Odrade Gondry (Contributor), Yanina Jansen (Contributor), Teofila Seremet (Contributor), Marleen Keyaerts (Contributor), Hendrik Everaert (Contributor), Bart Neyns (Contributor)14 dec 2018Activiteit: Talk or presentation at a conference
-
Correlation of baseline 18F-FDG-PET/CT parameters with the outcome of advanced melanoma patients treated with the pd-1 blocking monoclonal antibody pembrolizumab
Odrade Gondry (Speaker), Ibrahim Özdemir (Contributor), Yanina Jansen (Contributor), Gil Awada (Contributor), Julia Katharina Schwarze (Contributor), Teofila Seremet (Contributor), Hendrik Everaert (Contributor), Bart Neyns (Contributor), Marleen Keyaerts (Contributor)19 okt 2018Activiteit: Talk or presentation at a workshop/seminar
Scriptie
-
A single institution pilot trial of vaccination with an autologoeus TriMix-dendritic cell vaccine combined with sequential interferon alfa-2b or ipilumumab in patients with advanced melanoma
Auteur: Wilgenhof, S., Neyns, B. & De Greve, J., 2009Begeleider: Neyns, B. (Promotor) & De Greve, J. (Promotor)
Scriptie/masterproef: Master's Thesis
-
Autologous mRNA electroporated dendritic cell-based immunotherapy for melanoma patients.
Auteur: Wilgenhof, S., Neyns, B., Thielemans, K., Everaert, H., De Ridder, M., Gutermuth, J., de Vries, J., Svane, I. M. & Brochez, L., 29 jun 2017Begeleider: Neyns, B. (Promotor), Thielemans, K. (Promotor), Everaert, H. (Jury), Gutermuth, J. (Jury), De Ridder, M. (Jury), de Vries, J. (Externe persoon) (Jury), Svane, I. M. (Externe persoon) (Jury) & Brochez, L. (Externe persoon) (Jury)
Scriptie/masterproef: Doctoral Thesis
-
Bone marrow-induced survival: identifying novel targets in multiple myeloma.
Auteur: De Beule, N., Vanderkerken, K., Schots, H., Menu, E., Van Valckenborgh, E., Neyns, B., Van Riet, I., Laoui, D., Pals, S. & Offner, F., 24 apr 2018Begeleider: Vanderkerken, K. (Promotor), Schots, H. (Promotor), Menu, E. (Promotor), Van Valckenborgh, E. (Promotor), Neyns, B. (Jury), Van Riet, I. (Jury), Laoui, D. (Jury), Pals, S. (Externe persoon) (Jury) & Offner, F. (Externe persoon) (Jury)
Scriptie/masterproef: Doctoral Thesis
-
CT guided thermal ablation of malignant lesions: technique and evaluation of success
Auteur: Vandenbroucke, F., De Mey, J., Vandemeulebroucke, J., Buls, N., De Ridder, M., Cannie, M., Reynaert, H., Neyns, B., Lahoutte, T., Gérard, J. & Vandecaveye, V., 4 jul 2017Begeleider: De Mey, J. (Promotor), Vandemeulebroucke, J. (Externe persoon) (Co-promotor), Buls, N. (Co-promotor), De Ridder, M. (Jury), Cannie, M. (Jury), Reynaert, H. (Jury), Neyns, B. (Jury), Lahoutte, T. (Jury), Gérard, J. (Externe persoon) (Jury) & Vandecaveye, V. (Externe persoon) (Jury)
Scriptie/masterproef: Doctoral Thesis
-
Evaluating single domain antibodies specific for PD-L1 as cancer nuclear imaging and therapy agents
Auteur: Broos, K., Breckpot, K., Devoogdt, N., Keyaerts, M., De Gruijl, T., Vermaelen, K., Everaert, H., Menu, E. & Neyns, B., 11 okt 2019Begeleider: Breckpot, K. (Promotor), Devoogdt, N. (Promotor), Keyaerts, M. (Promotor), De Gruijl, T. (Externe persoon) (Jury), Vermaelen, K. (Externe persoon) (Jury), Everaert, H. (Jury), Menu, E. (Jury) & Neyns, B. (Jury)
Scriptie/masterproef: Doctoral Thesis